Experimental antibody drug tested for stubborn blood cancers, but study halted early
NCT ID NCT05285813
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called vibecotamab in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer did not respond to or came back after standard treatments. The drug is a special antibody designed to help the immune system attack cancer cells. The trial was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Frailty check may steer safer cancer care for seniors
- Can a tailored chemo cocktail outsmart a common leukemia?
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can a different immune drug cut viral infections after stem cell transplants?
- Can pressurized oxygen boost cord blood transplants?